Background: Viremic non-progressors (VNPs) are a rare group of ART-naive, HIV-infected individuals that remain asymptomatic with normal CD4+ T cell counts for >10 years despite high-level viremia, similar to natural hosts of SIV infection. Like natural SIV hosts, VNPs also maintain very low levels of central memory CD4+ T cell (TCM) infection, but the effects of immunologic characteristics of this rare clinical phenotype are unknown. Methodology: VNPs (n=9) were defined as: ART-naive, HIV duration >10 years, CD4+ T cell counts stably >500 cells/mm3 (and CD4% >15%), plasma HIV RNA levels (VL) stably > 104 copies/ml, and absence of AIDS-defining illness. We compared them to recently HIV-infected participants (< 2 years post-infection) with similar CD4+ T cell counts and VL who were expected to progress at a typical rate (“putative progressors”, n=110), untreated HIVinfected progressors with similar VL, but CD4+ T cell counts <500 cells/mm3 (n=26), and HIV-uninfected controls (n=24). We compared T cell activation (CD38+HLA-DR+), maturation (CCR7, CD45RA), PD-1 expression, and HIV-specific functional responses between groups. Results: VNPs were known to be HIV infected for a median of at least 22 years, and had higher median CD4+ T cell counts than both putative and chronic progressors (723 vs. 560 and 381, p ≤ 0.004), but also much higher CD8+ T cell counts (1737 vs. 859 and 986, p ≤ 0.001). VNPs had higher proportions of activated CD4+ and CD8+ T cells compared with HIV-uninfected controls (14% vs. 2% and 52% vs. 9%, p ≤ 0.001), comparable to putative and chronic progressors. The proportion of CD4+ T cells expressing PD-1 was higher in VNPs than putative progressors (24% vs. 16%, p = 0.006), driven by higher proportions of PD-1 expressing CD4+ TCM (CCR7-CD45RA+, p = 0.006) and TEM subsets (CCR7-CD45RA-, p = 0.01). Furthermore, in VNPs, the proportion of CD4+ T cells expressing PD-1 was associated with higher CD4+ T cell counts (r = 0.78, p = 0.02), while the opposite association was observed in chronic progressors (r = -0.62, p = 0.006). Despite a high proportion of CD4+ T cells expressing PD-1, VNPs had higher Gag-specific CD4+ T cell responses than putative progressors (TNFα+, p = 0.007). VNPs had lower proportions of PD-1 expressing CD8+ T cells than chronic progressors (p ≤ 0.05), and higher Gag-specific CD8+ T cell responses than putative and chronic progressors (TNFα+, p ≤ 0.05). Conclusions: Despite maintaining normal CD4+ T cell counts and low levels of CD4+ TCM infection, VNPs have abnormally high T cell activation and CD4+ TCM PD-1 expression. This may suggest that sustained proliferation without productive infection of TCM may contribute to the VNP phenotype. Regardless of the mechanism, the immunology of VNP in humans appears fundamentally distinct from that in natural hosts of SIV.